Latest Conference Articles

June 27th 2014, 12:18pm

Multinational Association of Supportive Care in Cancer International Symposium

A treatment intended to control chemotherapy-induced nausea and vomiting that combines netupitant and palonosetron demonstrated superior activity in complete response rates over oral palonosetron monotherapy.

June 27th 2014, 11:58am

Multinational Association of Supportive Care in Cancer International Symposium

For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.

June 27th 2014, 11:36am

ESMO Gastrointestinal Cancers Congress

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

June 27th 2014, 11:25am

Multinational Association of Supportive Care in Cancer International Symposium

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

June 27th 2014, 10:35am

ESMO Gastrointestinal Cancers Congress

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

June 27th 2014, 9:32am

ESMO Gastrointestinal Cancers Congress

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.

June 27th 2014, 9:21am

Multinational Association of Supportive Care in Cancer International Symposium

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

June 27th 2014, 8:07am

Multinational Association of Supportive Care in Cancer International Symposium

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

June 27th 2014, 7:42am

ESMO Gastrointestinal Cancers Congress

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

June 27th 2014, 7:16am

ESMO Gastrointestinal Cancers Congress

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.

June 27th 2014, 5:31am

Multinational Association of Supportive Care in Cancer International Symposium

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, discusses links between toxicities associated with anticancer drugs.

June 26th 2014, 12:46pm

Multinational Association of Supportive Care in Cancer International Symposium

Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).

June 26th 2014, 10:57am

ESMO Gastrointestinal Cancers Congress

Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.

June 26th 2014, 9:02am

ESMO Gastrointestinal Cancers Congress

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus

June 26th 2014, 8:11am

ESMO Gastrointestinal Cancers Congress

Four independent prognostic factors for improved overall survival in patients with locally advanced pancreatic cancer emerged from an analysis of the LAP 07 phase III trial.

June 26th 2014, 6:42am

Multinational Association of Supportive Care in Cancer International Symposium

Ã…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.

June 25th 2014, 2:38pm

ESMO Gastrointestinal Cancers Congress

Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.

June 25th 2014, 7:22am

ESMO Gastrointestinal Cancers Congress

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

June 10th 2014, 8:02am

ASCO Annual Meeting

Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.

June 6th 2014, 2:02pm

ASCO Annual Meeting

The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.